Skip to content
Featured on Startup Fame

Science Corporation raises $400M Series D at $3.5B valuation for PRIMA vision chip and brain sensor

Science Corporation, a medical technology startup founded by former Neuralink president Max Hodak, has raised $400 million in a Series D funding round, bringing its valuation to $3.5 billion. The investment will support U.S. approval and commercialization of its PRIMA vision-restoration device and development of a bio-hybrid brain sensor.

Editor, Lazyfounder

Published 3 min read
Science Corporation raises $400M Series D at $3.5B valuation for PRIMA vision chip and brain sensor
Image: Kimberly White/Getty Images for TechCrunch via source

Record Series D for brain-machine interface startup

Science Corporation, a medical technology startup founded by Max Hodak, former president of Neuralink, has secured $400 million in a Series D funding round. The company is now valued at $3.5 billion, according to a person familiar with the deal cited by TechCrunch.

Who invested in the round

The round was led by a diverse group of investors, including venture firms Khosla Ventures and Y Combinator, healthcare operator Tenet Healthcare, the Ackman Oxman Institute, 885 Capital, and PLC Neurotech. This mix of financial and strategic backers highlights growing interest in neurotechnology from both traditional venture capital and healthcare providers.

PRIMA device targets FDA approval

The funding will primarily support U.S. regulatory approval for Science Corporation’s PRIMA device, a wireless chip designed to restore vision in patients with degenerative eye conditions such as age-related macular degeneration and Stargardt’s disease. PRIMA is already approved in Europe and available in Germany, with clinical trials underway for new indications, including Stargardt’s disease.

The company plans to seek FDA approval under the Humanitarian Device Exemption, which allows expedited review for treatments targeting rare conditions. Science Corporation has already secured FDA agreement that advanced macular degeneration in both eyes qualifies as sufficiently uncommon for this pathway.

Bio-hybrid sensor enters human trial design

Beyond its vision-restoration technology, Science Corporation is developing a bio-hybrid sensor that combines cultured neurons with silicon to enable direct brain interaction. Initial human trials for the sensor are being designed in collaboration with Murat Günel, a neurosurgery professor at Yale. The device aims to address conditions like Parkinson’s disease, brain injuries, and other neurological disorders.

The $400 million round provides capital to advance both PRIMA and the bio-hybrid sensor through clinical development, positioning the company as a competitor in the broader brain-machine interface space alongside companies like Neuralink and Synchron.

Contrast with competitors in neurotechnology

Science Corporation’s latest funding round follows a period of challenges for competitors in the brain-machine interface space. In June, Synchron paused its second-generation brain-implant trials to address a hardware issue and restructured its team. The contrast highlights Science Corporation’s ability to attract substantial investment while advancing multiple product lines simultaneously.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Science Corporation’s $400 million Series D and $3.5 billion valuation mark the largest recent funding event in brain-machine interface technology, setting a new benchmark for pre-commercial neurotech startups. The round also signals strong investor confidence in devices targeting rare conditions under the FDA’s Humanitarian Device Exemption, a pathway that could accelerate U.S. market entry for PRIMA and similar products. Founders in medical technology should note the mix of venture firms and healthcare operators among the backers, which may indicate a growing trend toward strategic partnerships between providers, payers and startups in neurotechnology.

Sources

  1. TechCrunch · 2026-11-17
    Science Corporation’s brain tech is worth $3.5 billion after new funding

This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.

About the author

Editor, Lazyfounder

Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.

More stories by Tarun Mottlia

Get the LazyFounder Brief

Startup, funding and AI news in a five-minute read. Join the early-access list.

Lazy Founder - Powered by Blogy.in

Contact us

Have a story tip, correction or partnership idea?

Write to us at tarun.kumar@blogy.in or talk to the founder directly. We read every message.

Contact us